A Randomized Comparison of Intensive Maintenance Treatment for Adult Acute Myelogenous Leukemia Using Either Cyclic Alternating Drugs or Repeated Courses of the Induction-Type Chemotherapy: AML-6 Trial of the EORTC Leukemia Cooperative Group

  • U. Jehn
  • R. Zittoun
  • S. Suciu
  • D. Fiere
  • C. Haanen
  • M. Peetermans
  • B. Löwenberg
  • R. Willemze
  • G. Solbu
  • P. Stryckmans
  • EORTC Leukemia Cooperative Group
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

Standard induction treatment of patients with de novo acute myelogenous leukemia (AML) results in a complete remission (CR) rate of 60%–80%. However, remission duration is usually short with a relapse rate of about 70% within the first 2 years independent of various consolidation and maintenance modalities. The rate of long-term remitters at 4 – 5 years is no higher than 20%–30%. The role of maintenance treatment is controversial. Generally, repeated short courses of intravenous or subcutaneous cytarabine with thioguanine or daunorubicin are given monthly for 2–3 years. Numerous controlled and uncontrolled trials with few exceptions have failed to demonstrate a substantial benefit in patients receiving maintenance therapy compared with those receiving induction and consolidation alone [1–11]. Two other studies [12, 13] reported superior results with maintenance therapy, but this was probably due to unexpectedly poor results among controls [14].

Keywords

Toxicity Urea Leukemia Oncol Androgen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin R, Jacobs A, Gale RP et al. (1984) Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy.Google Scholar
  2. Lancet 1:894Google Scholar
  3. 2.
    Sauter C, Berchtold W, Fopp M et al. (1984) Acute myelogenous leukemia: maintenance chemotherapy after early consolidation treatments does not prolong survival. Lancet 1: 379PubMedCrossRefGoogle Scholar
  4. 3.
    Marcus RE, Catovsky D, Goldman JM et al. (1984) Maintenance and consolidation chemotherapy in AML. Lancet 1: 686PubMedCrossRefGoogle Scholar
  5. 4.
    Embury SH, Elias L, Heller DH et al. (1979) Remission maintenance therapy in acute myelogenous leukemia. West J Med 126: 267Google Scholar
  6. 5.
    Rees JKG, Hayhoe FGJ (1984) Treatment of acute myeloid leukemia following remission. Results of a large cooperative study in the UK. Proc Am Soc Clin Oncol 3: 190 (abstract)Google Scholar
  7. 6.
    Omura GA, Vogler WR, Lefanate J et al. (1982) Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer 49: 1530PubMedCrossRefGoogle Scholar
  8. 7.
    Appelbaum FR, Dahlberg S, Thomas ED et al. (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphocytic leukemia. Ann Intern Med 101: 581PubMedGoogle Scholar
  9. 8.
    Vogler WR, Winton EF, Gordon DS et al. (1984) A randomized comparison of post-remission therapy in acute myelogenous leukemia: a southeastern Cancer Study. Blood 63: 1039PubMedGoogle Scholar
  10. 9.
    Toronto Leukemia Study Group (1988) Survival in acute myeloblasts leukemia is not prolonged by remission maintenance or early re-induction chemotherapy. Leuk Res 12: 195Google Scholar
  11. 10.
    Hayat M, Jehn U, Willemze R et al. (1986) A randomized comparison of maintenanceGoogle Scholar
  12. 283.
    treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the E.O.R.T.C. Cancer 58: 617Google Scholar
  13. 11.
    Zittoun R, Jehn U, Fiere D et al. (1989) Alternating versus repeated postremission treatment in adult acute myelogenous leukemia: a randomized study of the E.O.R.T.C. Leukemia Cooperative Group. Blood 73: 896PubMedGoogle Scholar
  14. 12.
    Biichner T, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia. J Clin Oncol 3: 1583Google Scholar
  15. 13.
    Cassileth PA, Harrington DP, Hines JD et al. (1988) Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol 6: 583PubMedGoogle Scholar
  16. 14.
    Champlin R, Gale GP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69:1551 15. Dutcher JP, Wiernik PH, Markus S et al. (1988) Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: an eight year follow-up. Leukemia 2: 413Google Scholar
  17. 16.
    Champlin RE, Ho WG, Gale RP (1985) Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102: 285Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • U. Jehn
  • R. Zittoun
  • S. Suciu
  • D. Fiere
  • C. Haanen
  • M. Peetermans
  • B. Löwenberg
  • R. Willemze
  • G. Solbu
  • P. Stryckmans
  • EORTC Leukemia Cooperative Group

There are no affiliations available

Personalised recommendations